Recent Finacing
Recent Raise
Janpix develops monovalent small-molecule degraders of STAT3/STAT5 transcription factors for hematological and solid tumors, advancing preclinical candidates toward clinical development from its Cambridge, MA base.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Janpix.
